Skip to main content
Clinical Trials/NCT01185912
NCT01185912
Completed
Not Applicable

Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia

Turku University Hospital1 site in 1 country20 target enrollmentJanuary 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiomyocyte Apoptosis
Sponsor
Turku University Hospital
Enrollment
20
Locations
1
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Retrograde cardioplegia during heart surgery is associated with inadequate myocardial protection. In experimental animal study retrograde cardioplegia induces more cardiomyocyte apoptosis when compared to antegrade cardioplegia. 20 volunteer patients under going elective aortic valve surgery will be divided in to two groups: 10 patients receiving only antegrade cardioplegia and 10 patients receiving only retrograde cardioplegia. Pre- and post-operatively cardiac MRI and cardiac ultrasound will be performed. During the surgery ventricular muscle samples will be taken in order to assess cardiomyocyte apoptosis. Aims of the study: 1. whether the cardiomyocyte apoptosis is significantly more induced after retrograde cardioplegia than antegrade cardioplegia, 2. whether the amount of apoptotic cardiomyocytes correlates to conventional markers of myocardial injury after cardiac surgery, 3. whether the extent of irreversible myocardial damage by apoptosis correlates to post-ischemic contractile dysfunction after cardiac surgery, as measured with echocardiography, 4. whether the amount of cardiomyocyte apoptosis correlates to long term outcome and cardiac function as measured with MRI.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
January 2010
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Markus Malmberg

MD

Turku University Hospital

Eligibility Criteria

Inclusion Criteria

  • aortic valve stenosis or combined aortic valve disease

Exclusion Criteria

  • angiographically verified hemodynamically significant coronary artery disease impaired left ventricular function (left ventricular ejection fraction \<50%) surgery including additional procedures other than aortic valve replacement cancer

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials